natgillin/translations-raw huggingface dataset:
This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level.
Namen tega izobraževalnega paketa je povečati zavedanje o pomembnih znanih tveganjih za nastanek raka mehurja in srčnega popuščanja ter celokupna priporočila, namenjena optimizaciji meje med koristjo in tveganjem pri vsakem bolniku.
This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level.
Namen tega izobraževalnega paketa je povečati zavedanje o pomembnih znanih tveganjih za nastanek raka mehurja in srčnega popuščanja, ter celokupna priporočila, namenjena optimizaciji meje med koristjo in tveganjem pri vsakem bolniku,
This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level.
To izobraževalno gradivo je namenjeno ozaveščanju o pomembnih ugotovljenih tveganjih za rak mehurja in srčno popuščanje ter o splošnih priporočilih, da bi dosegli najboljše razmerje med koristjo in tveganjem na ravni bolnika.
This educational programme will include: recommendations regarding the general handling and disposal measures for Qutenza
Izobraževalni program vključuje: priporočila o splošnem rokovanju z zdravilom Qutenza in ukrepih za njegovo odstranjevanje,
This effect at the 300 mg dose of canagliflozin may, in part, be due to local inhibition of intestinal SGLT1 (an important intestinal glucose transporter) related to transient high concentrations of canagliflozin in the intestinal lumen prior to medicinal product absorption (canagliflozin is a low potency inhibitor of the SGLT1 transporter).
Do takega delovanja odmerka 300 mg kanagliflozina lahko pride deloma zaradi lokalnega zaviranja prenašalca SGLT1 v črevesju (pomembnega črevesnega prenašalca glukoze), ki je povezano s prehodno visoko koncentracijo kanagliflozina v svetlini črevesa, preden se zdravilo absorbira (kanagliflozin je šibak zaviralec prenašalca SGLT1).
This effect has been observed with the PTT-Lupus Anticoagulant (LA) test and Standard Target Activated Partial Thromboplastin time (STA-PTT) Automate tests from Diagnostica Stago, and the HemosIL APTT-SP liquid and HemosIL lyophilised silica tests from Instrumentation Laboratories.
Tak učinek so opazili pri naslednjih testih: PTT-LA (Lupus Anticoagulant) in STA- PTT (Standard Target Activated Partial Thromboplastin time) Automate proizvajalca Diagnostica Stago, ter HemosIL APTT-SP tekočina in HemosIL liofilizirani silicijev dioksid proizvajalca Instrumentation Laboratories.
This effect is also seen with other agents acting on the renin- angiotensin system, such as ACEI and ARBs.
Ta učinek so opažali tudi pri drugih učinkovinah, ki delujejo na sistem renin-angiotenzin, kot so zaviralci angiotenzinske konvertaze (zaviralci ACE) in zaviralci angiotenzinskih receptorjev II.
This effect is also seen with other agents acting on the renin- angiotensin system, such as ACEI and ARBs.
Ta učinek so opažali tudi pri drugih učinkovinah, ki delujejo na sistem renin-angiotenzin, kot so zaviralci angiotenzinske konvertaze (zaviralci ACE) in zaviralci angiotenzinskih receptorjev.
This effect is also seen with other agents acting on the renin- angiotensin system, such as ACEIs and ARBs.
Ta učinek so opažali tudi pri drugih učinkovinah, ki delujejo na sistem renin-angiotenzin, kot so zaviralci angiotenzinske konvertaze (zaviralci ACE) in antagonisti angiotenzinskih receptorjev II.
This effect is also seen with other agents acting on the renin- angiotensin system, such as ACEIs and ARBs.
Ta učinek so opažali tudi pri drugih učinkovinah, ki delujejo na sistem renin-angiotenzin, kot so zaviralci angiotenzinske konvertaze (zaviralci ACE) in zaviralci angiotenzinskih receptorjev II.
This effect is also seen with other agents acting on the renin- angiotensin system, such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers.
Ta učinek so opažali tudi pri drugih učinkovinah, ki delujejo na sistem renin-angiotenzin, kot so zaviralci angiotenzinske konvertaze (zaviralci ACE) in zaviralci angiotenzinskih receptorjev.
This effect is also seen with other medicinal products acting on the RAAS, such as ACEIs and ARBs.
Ta učinek so opažali tudi pri drugih zdravilih, ki delujejo na sistem renin-angiotenzin-aldosteron, kot so zaviralci ACE in antagonisti angiotenzinskih receptorjev.
This effect is known from other active substances with cationic amphiphilicproperties.
Ta učinek je poznan pri zdravilnih učinkovinah s kationskimi amfifilnimi lastnostmi.
This effect is likely to be of clinical concern only when prasugrel is co- administered with medicinal products for which CYP2B6 is the only metabolic pathway and have a narrow therapeutic window (e.g. cyclophosphamide, efavirenz).
Ta učinek je klinično pomemben samo, kadar prasugrel dajemo sočasno z zdravili, za katere je edina pot presnove CYP2B6 in imajo ozko terapevtsko širino (npr. ciklofosfamid, efavirenz).
This effect is maintained in the co- formulation with insulin aspart and does not interfere with the rapid-acting insulin aspart monomers.
Ta učinek se v skupnem pripravku z insulinom aspart ohrani in ne ovira monomerov hitrodelujočega insulina aspart.
This effect is usually mild or moderate.
Ta učinek je ponavadi blag ali zmeren.
This effect on serum creatinine, leading to a decrease in the estimated creatine clearance, should be taken into consideration when Tybost is administered to patients in whom the estimated creatinine clearance is used to guide aspects of their clinical management, including adjusting doses of co-administered medicinal products.
Ta učinek na serumski kreatinin, ki povzroči zmanjšanje ocenjenega očistka kreatinina, je treba upoštevati pri dajanju zdravila Tybost bolnikom, pri katerih se ocenjeni očistek kreatinina uporablja kot smernica za vodenje njihove klinične obravnave, vključno s prilagajanjem sočasno odmerjanih zdravil.
This effect seems to be due to an ADCP (4-Amino-3,5-dichloro-pyridine) N-oxide intermediate specifically formed in rodent olfactory mucosa, with special binding affinity in these species (i.e. mouse, rat and hamster).
Zdi se, da je ta učinek posledica vmesne spojine ADCP (4-amino 3,5-diklor piridin) N-oksida, ki nastaja specifično na vohalni sluznici glodavcev in ima posebno vezavno afiniteto pri teh vrstah (t.j. miš, podgana in hrček).
This effect should be taken into account and managed when adding or withdrawing these anti-epileptic drugs from a patient’s treatment regimen.
Ta učinek je treba upoštevati in nadzorovati, kadar za zdravljenja bolnika ta antiepileptična zdravila dodamo ali odvzamemo.
This effect was driven by PsA Study 1.
Ta učinek se je pokazal v
This effect was maintained for almost one year.
Ta učinek se je ohranil skoraj eno leto.
This effect was maintained for up to 12 weeks.
Ta učinek je trajal do 12 tednov.
This effect was not confirmed in vivo in the Mouse Micronucleus Test in the rat Unscheduled DNA Synthesis (UDS) test.
Tega učinka niso potrdili in vivo pri testu mikronukleusa pri miših in pri testu nenačrtovane sinteze DNA (UDS – Unscheduled DNA Synthesis) pri podganah.
This effect was not considered clinically important.
Ti učinki ne veljajo za klinično pomembne.
This effect was not observed in conscious non-sedated pigs, or in any other species, including man.
Tega učinka niso opažali niti pri nesediranih prašičih, ki so bili pri zavesti, niti pri kakšni drugi vrsti, vključno s človekom.
This effect was only observed at high doses in rodents.
Ta učinek so opazili le pri visokih odmerkih pri glodavcih.
This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.
Ta učinek je bil izrazit pri mlajših dojenčkih, z naraščanjem let je upadal in postal zanemarljiv okoli 4. leta starosti.
This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicinal products or of conditions such as intestinal obstruction, Reye’s syndrome and brain tumour.
Če se to pojavi pri človeku, lahko prikrije znake in simptome prevelikega odmerjanja nekaterih zdravil ali stanj, kot so ileus, Reyev sindrom in možganski tumor.
This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicines or of conditions such as intestinal obstruction, Reye’s syndrome, and brain tumour.
Če se to pojavi pri človeku, lahko prikrije znake in simptome prevelikega odmerjanja določenih zdravil ali stanj, kot so obstrukcija črevesja, Reyev sindrom in možganski tumorji.
This enables diseases related to Parkinson’s disease to be distinguished from essential tremor, and for Lewy body dementia to be distinguished from Alzheimer’s disease.
To omogoča ločiti obolenja, povezana s Parkinsonovo boleznijo, od esencialnega tremorja, ter demenco z Lewyjevimi telesci od Alzheimerjeve bolezni.
This enables Zevalin to deliver radiation more specifically to the cancerous B–cells.
To zdravilu Zevalin omogoča, da se radioaktivno sevanje posebej osredotoči na rakave celice B..
This encourages cancer to develop by allowing uncontrolled division of cells.
To omogoči nenadzorovano delitev celic in spodbudi nastanek raka.
This ensures that adequate amounts of dexamethasone reach the area inside the eye where the swelling in macular oedema and uveitis occurs.
To zagotavlja, da v predel v očesu, ki je otekel zaradi makularnega edema ali uveitisa, prodre dovolj deksametazona.
This ensures that text is readable until last tablet of blister card is used.
To zagotavlja, da ostane besedilo vidno, dokler ni porabljena zadnja tableta v pretisnem omotu.
This ensures that the full dose of insulin has been delivered.
To zagotovi, da bolnik dobi celoten odmerek insulina.
This ensures that the full dose of insulin has been delivered.
To zagotovi, da je bil dan celoten odmerek insulina.
This ensures that the full dose will be delivered.
To zagotovi, da je bil dan celoten odmerek.
This ensures that the medicine is shaken in the correct way and for long enough to make up a ‘dispersion’ of microspheres of perflutren gas of the right size to get a good quality image.
S tem se zagotovi, da se zdravilo stresa na pravilen način in dovolj dolgo, da nastane »disperzija« mikrosfer s plinom perflutrenom ustrezne velikosti, da se pridobi kakovostna slika.
This ensures that the medicine is shaken in the correct way and for long enough to make up a ‘dispersion’ of microspheres of perflutren gas of the right size to get a good quality image.
S tem se zagotovi, da se zdravilo stresa na pravilen način in dovolj dolgo, s čimer se ustvari „disperzija“ mikrosfer plina perflutrena pravilne velikosti, ki omogoči kakovostno sliko.
This ensures the high accuracy of this system, as calculation of the isotopic content in carbon dioxide is done with respect to an independent standard.
To zagotavlja visoko natančnost sistema, kajti vsebina izotopa v ogljikovem dioksidu je izračunana glede na neodvisni standard.
This enzyme helps the body control levels of glucosylceramide.
S pomočjo tega encima telo nadzira ravni glukozilceramida.
This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues.
Ta encim nastaja v tkivu mod, nadledvičnih žlez in tumorskega tkiva prostate, kjer je njegova prisotnost potrebna za biosintezo androgenov.
This enzyme is found in some receptors on the surface of leukaemia cells where it is involved in stimulating the cells to divide uncontrollably.
Ta encim se nahaja v nekaterih receptorjih na površini levkemičnih celic, kjer sodeluje pri spodbujanju njihovega nenadzorovanega razmnoževanja.
This enzyme is involved in producing substances called prostaglandins, which are involved in pain and
Ta encim sodeluje pri proizvodnji snovi, imenovanih prostaglandini, ki sodelujejo pri bolečinah in vnetjih.
This enzyme is involved in producing substances called prostaglandins, which are involved in pain and inflammation.
Ta sodeluje pri tvorbi snovi, imenovanih prostaglandini, ki sodelujejo pri nastanku bolečine in vnetja.
This enzyme normally breaks down a fat called glucosylceramide (or glucocerebroside), and without it, the fat builds up in the body, typically in the liver, spleen and bone.
Ta encim običajno razgrajuje maščobo, imenovano glukozilceramid (ali glukocerebrozid), brez njega pa se ta maščoba kopiči v telesu, praviloma v jetrih, vranici in kosteh.
This enzyme normally breaks down sugar stored as glycogen into glucose that can be used for energy by the body’s cells.
Ta encim navadno pretvarja sladkor, ki je shranjen kot glikogen, v glukozo, ki jo telesne celice uporabljajo za energijo.
This enzyme plays a role in the growth, migration and survival of white blood cells but is overactive in blood cancers, where it enables the survival of the cancer cells.
Ta encim vpliva na rast, migracijo in preživetje belih krvnih celic, vendar je pri krvnih rakih čezmerno dejaven, s čemer omogoča preživetje rakavih celic.
This enzyme plays a role in triggering the production of messenger molecules in the immune system (the body’s natural defences) called cytokines, which are involved in the inflammation and other processes that cause psoriasis and psoriatic arthritis.
Ta encim sodeluje pri proženju tvorbe signalnih molekul, imenovanih citokini, v imunskem sistemu (naravni obrambi telesa), citokini pa sodelujejo pri vnetnih in drugih procesih, ki povzročajo psoriazo in psoriatični artritis.
This evaluation included data from patients that were initially randomised to ruxolitinib (N=301) and patients that received ruxolitinib after crossing over from control treatment arms (N=156).
V to oceno so bili vključeni tako podatki bolnikov, ki so bili takoj randomizirani na prejemanje ruksolitiniba (N=301), kot bolnikov, ki so začeli prejemati ruksolitinib šele po prehodu iz kontrolnih študijskih skupin (N=156).
This evaluation should address a patient’s cardiovascular status including blood pressure and heart rate, documenting comprehensive history of concomitant medications, past and present co-morbid medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and accurate recording of pre-treatment height and weight on a growth chart (see section 4.4).
To naj bo ocenjevanje bolnikovega kardiovaskularnega statusa, vključno s krvnim tlakom in srčno frekvenco, dokumentiranje izčrpne anamneze sočasnih zdravil, preteklih in sedanjih sočasnih medicinskih in psihiatričnih bolezni ali simptomov, družinske anamneze nenadne srčne smrti/smrti iz neznanega vzroka in natančno zabeleženje telesne višine in telesne mase pred zdravljenjem na rastni krivulji (glejte poglavje 4.4).
This evaluation should include a detailed medical history with personal history of tuberculosis or possible previous contact with tuberculosis and previous and/or current immunosuppressive therapy.
Ta ocena naj vključuje podrobno zdravstveno anamnezo, z osebno anamnezo glede tuberkuloze ali morebitnih predhodnih stikov s tuberkulozo in morebitno predhodno in/ali sedanjo imunosupresivno terapijo.
This event appears to be related to the use of the spray device at higher than recommended pressures and/or in close proximity to the tissue surface.
Kaže, da je ta dogodek povezan z uporabo pršilnikov s tlakom, ki je višji od priporočenega, in/ali preblizu površine tkiva.
This event appears to be related to the use of the spray device at higher than recommended pressures and/or in close proximity to the tissue surface.
Zdi se, da je ta pojav povezan z uporabo pršilnika s tlaki, ki so višji od priporočenega, ali/in z uporabo v neposredni bližini tkivne površine.
This event is common (may affect up to 1 in 10 women).
Ta pojav je pogost (pojavijo se lahko pri največ 1 od 10 žensk).
This event is generally reversible after sunitinib discontinuation.
Le-ta običajno izgineta, ko z zdravljenjem s sunitinibom prekinete.
This event is uncommon (may affect up to 1 in 100 women).
Ta pojav je občasen (pojavijo se lahko pri največ 1 od 100 žensk).
This exposure for the 0.15 mg/kg dose can be achieved with a weight-band- based dose adjustment using an 8 mg dose for body weight 38 to less than 62 kg and a 12 mg dose for body weight 62 to 114 kg, yielding a mean exposure of 187 (range = 148-220) ng•h/mL.
To izpostavljenost lahko za odmerek 0,15 mg/kg dosežemo s prilagoditvijo odmerka na podlagi razponov telesne mase, tako da pri telesni masi od 38 do manj kot 62 kg uporabimo odmerek 8 mg, pri telesni masi od 62 do 114 kg pa odmerek 12 mg, s čimer dobimo povprečno izpostavljenost 187 (razpon = 148-220) ng•h/ml.
This exposure would result in a final dose of 0.5 mg/kg in a 10 kg infant, assuming 100% absorption.
Ob predpostavki 100% absorpcije bi ta izpostavljenost pri 10 kg otroku pomenila končni odmerek 0,5 mg/kg.
This eye problem is inherited – this means it runs in families.
Ta težava z očmi je dedna, kar pomeni, da se prenaša v družini.
This feeling may be even worse when you sleep for less than 7 to 8 hours after taking your medication or if you are already taking another central nervous system depressant or if you are drinking alcohol (see ‘other medicines and Sonata’).
Vse to je lahko še slabše, če ste po zaužitju zdravila spali manj kot 7 do 8 ur, če že jemljete druge zaviralce osrednjega živčevja ali če uživate alkohol (glejte odstavek »Druga zdravila in zdravilo Sonata«).
This fill volume has been established during the development of docetaxel to compensate for liquid loss during preparation of the premix due to foaming, adhesion to the walls of the vial and "dead-volume".
Ta polnilni volumen je bil določen med razvojem docetaksela za nadomestitev tekočine, ki se izgubi med pripravo osnovne raztopine zaradi penjenja, adhezije na stene viale in »mrtvega volumna«.
This fill volume has been established during the development of docetaxel to compensate for liquid loss during preparation of the premix due to foaming, adhesion to the walls of the vial and "dead-volume".
Ta polnilni volumen je bil določen med razvojem docetaksela za nadomestitev tekočine, ki se izgubi med pripravo osnovne raztopine(glejte poglavje 4) zaradi penjenja, adhezije na stene viale in »mrtvega volumna«.
This finding is not considered relevant to human safety since the Harderian gland is not present in man.
Ta ugotovitev ni pomembna za varnost pri človeku, saj Harderjeva žleza pri njem ni prisotna.
this finding is unknown.
Klinični pomen teh ugotovitev ni znan.
This finding might be related to the inability to perform a progressive loading under non- weight bearing conditions post-surgery in these models and therefore cannot be fully extrapolated as such to the human situation.
Ugotovitve so morda povezane z nezmožnostjo postopnega obremenjevanja v pogojih pooperativne neobremenitve pri teh modelih in jih zato ni mogoče v celoti ekstrapolirati na situacijo človeka.
This Finnish Extension Study (FES) included a subset of 20,736 subjects that had been enrolled previously in REST.
V podaljšek študije na Finskem (FES – Finnish Extension Study) je bilo vključenih 20.736 oseb, ki so bile že prej vključene v študijo REST.
This first dose of 400 mg Bronchitol should only be given under the supervision of a qualified healthcare professional in a setting where the patient’s breathing can be properly monitored and facilities for resuscitation are available.
Ta prvi, 400-miligramski, odmerek zdravila Bronchitol se lahko daje samo pod nadzorom usposobljenega zdravstvenega delavca v okoliščinah, v katerih je mogoče ustrezno spremljati bolnikovo dihanje in kjer je na voljo oprema za oživljanje.
This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar doses.
Ta fiksna kombinacija treh učinkovin (abakavirja, lamivudina in zidovudina) nadomešča uporabo enakih odmerkov vsake posamezne učinkovine.
This followed a review of data that became available since its authorisation including data from the PALLAS study.1
Zaradi tega je bilo treba pregledati podatke, ki so bili dani na voljo od odobritve zdravila, vključno s podatki iz študije PALLAS.1
This formulation is not suitable for infants less than 1 year old.
Ta pripravek ni primeren za dojenčke, mlajše od 1 leta.
This four-week period is one ‘cycle’.
To štiritedensko obdobje je en cikel.
This gas mixture can improve heart function and increase the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches the blood.
Ta mešanica plinov lahko izboljša delovanje srca in poveča pretok krvi v pljučih, kar lahko pripomore k povečanju količine kisika, ki pride v kri.
This gives a total of 21 capsules per pack.
To pomeni skupno 21 kapsul na pakiranje.
This gives a total of 7 or 21 capsules per pack.
To pomeni skupno 7 ali 21 kapsul na pakiranje.
This group of medical terms may involve the same underlying pathophysiology (e.g. arterial thromboembolic reactions include cerebrovascular accident, myocardial infarction, transient ischaemic attack and other arterial thromboembolic reactions). c Based on a substudy from NSABP C-08 with 295 patients d For additional information refer below within section "Further information on selected serious adverse reactions." e Recto-vaginal fistulae are the most common fistulae in the GI-vaginal fistula category. f Observed in pediatric population only
patofiziologijo (npr. arterijski trombembolični neželeni učinki vključujejo cerebrovaskularni zaplet, miokardni infarkt, tranzitorno ishemično atako in druge arterijske trombembolične neželene učinke). c Na podlagi podštudije NSABP C-08 z 295 bolnicami. d Za nadaljnje informacije glejte spodnje podpoglavje »Dodatne informacije o določenih resnih neželenih učinkih«. e Rektovaginalne fistule so najpogostejše fistule v skupini fistul med prebavili in nožnico. f Opaženo samo pri pediatrični populaciji.
This group of medicines cause new bone to grow at the location where the surgeon has placed (implanted) it.
Ta skupina zdravil povzroča rast nove kosti na mestu, kjer ga je vstavil (vsadil) kirurg.
This grouping of reactions were reported in 3.2% and 1.8% of patients who received dapagliflozin 10 mg and placebo, respectively.
Ta skupina učinkov je bila opisana pri 3,2 % bolnikov, ki so prejemali 10 mg dapagliflozina, in pri 1,8 % tistih, ki so prejemali placebo.
This half-life may vary from patient to patient.
Razpolovna doba se lahko razlikuje od bolnika do bolnika.
This happens automatically because of a vacuum in the powder vial.
To poteka samodejno, ker je v viali s praškom vakuum.
This happens usually in one of the eyes.
Do tega običajno pride v enem očesu.
This happens when the tip of your catheter is fixed or in very close proximity to your liver.
To se zgodi, če je konica katetra nameščena v jetrih ali njihovi neposredni bližini.
This has been reported among patients receiving DaTSCAN into a small vein
O tem so poročali pri bolnikih, ki so zdravilo DaTSCAN prejeli v majhno veno.
This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: metformin reduces total cholesterol, LDLc and triglyceride levels.
To je bilo v terapevtskih odmerkih dokazano v kontroliranih srednjeročnih in dolgoročnih kliničnih študijah: metformin zmanjša koncentracijo celotnega holesterola, holesterola LDL in trigliceridov.
This has led to the identification of cholic acid as a tumour promoter, considered to be via the hyperprofileration of colorectal epithelium in the presence of secondary bile acids.
S tem so ugotovili, da je holna kislina promotor tumorjev, in menijo, da se to zgodi zaradi hiperproliferacije kolorektalnega epitelija ob prisotnosti sekundarnih žolčnih kislin.
This has not been seen in any patient treated with Strimvelis; however, during long-term follow up your doctor has been advised to monitor you (or your child) for any signs of leukaemia.
To se ni zgodilo pri nobenem bolniku, ki je prejemal zdravilo Strimvelis, vendar pa je med dolgotrajnim spremljanjem priporočeno, da zdravnik vas (ali vašega otroka) spremlja glede kakršnih koli znakov levkemije.